Beactica Receives Regulatory Support for BEA-17 Development in First Swedish Medical Products Agency Advisory Meeting
Key Insights
Beactica Therapeutics (search) conducted its first scientific advisory meeting with the Swedish Medical Products Agency (search) regarding BEA-17, receiving support for preclinical development plans aimed at enabling human dosing.
BEA-17 is a first-in-class small molecule targeted degrader of lysine demethylase 1 (search) (LSD1 (search)) that has shown promising potentiation of immune-modulating treatments in animal cancer (search) models.
The drug candidate has demonstrated good blood-brain-barrier penetration and oral availability, and has been granted FDA Orphan Drug Designation for glioblastoma (search) treatment.
Beactica Therapeutics (search) AB announced that it has successfully completed its first scientific advisory meeting with the Swedish Medical Products Agency (search) regarding its lead drug candidate BEA-17, receiving regulatory support for its preclinical development plans aimed at enabling human dosing. The Swedish precision medicine company also held positive discussions regarding the design and setup of a first clinical trial with the investigational compound.
"It is an important milestone for BEA-17 and Beactica to have completed the first formal meeting with regulatory authorities. It was a successful meeting where we received support for our plans, and we now have a clear picture of what needs to be done in the continued work towards a planned clinical trial application," said Beactica's CEO, Dr Per Källblad.
Novel Mechanism of Action Shows Promise in Cancer Models
BEA-17 represents a first-in-class small molecule targeted degrader of lysine demethylase 1 (search) (LSD1 (search)) and its co-factor CoREST (search). In syngeneic animal models of cancer (search), the compound has demonstrated promising potentiation of immune-modulating treatments across several cancer forms, including anti-PD1 (search) checkpoint inhibitors in colon cancer (search) (CT26) and standard of care treatments combining temozolomide and radiation in glioblastoma (search) (GL261).
Pharmacokinetic studies of BEA-17 have revealed favorable drug properties, showing good blood-brain-barrier penetration and oral availability. These characteristics are particularly significant for treating brain cancers, where drug delivery across the blood-brain barrier remains a major therapeutic challenge.
FDA Orphan Drug Designation for Glioblastoma
The U.S. Food and Drug Administration (search) has granted BEA-17 Orphan Drug Designation for the treatment of glioblastoma (search) (GBM), recognizing the significant unmet medical need in this aggressive brain cancer (search). BEA-17 remains investigational and is not approved anywhere globally, with its efficacy and safety in humans yet to be established.
Eclipsor Platform Technology
Beactica Therapeutics (search) is a privately held precision medicine company developing a pipeline of novel small molecule therapeutics for diseases with significant unmet medical need. The company's approach centers around its proprietary Eclipsor™ platform, which enables the efficient development of allosteric modulators and targeted protein degraders. Beactica aims to deliver value to patients and shareholders by advancing its programs to clinical proof of concept.